Inactive Instrument

Highlights ImmunoCellular Therapeutics Ltd OTC Bulletin Board

Equities

IMUC

US4525361055

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2023	EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	CI
2023	EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	06/09/23	CI
EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	02/08/23	CI
EOM Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	20/12/22	CI
EOM Pharmaceuticals Holdings, Inc. has filed an IPO in the amount of $25 million.	24/06/22	CI
EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. in a reverse merger transaction.	01/12/21	CI
Reverse Split: 1 of 10	15/09/20	FA
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	16/08/18	CI
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	14/05/18	CI
ImmunoCellular Therapeutics, Ltd. Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program	12/04/18	CI
ImmunoCellular Therapeutics, Ltd. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	13/03/18	CI
ImmunoCellular Therapeutics, Ltd. Achieves Stem-to-T-Cell Research Immuno-Oncology Program	13/12/17	CI
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	21/11/17	CI
Immunocellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	14/08/17	CI
ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial	21/06/17	CI
ImmunoCellular Therapeutics, Ltd. Announces Data from ICT-121 Phase 1 Trial in Recurrent Glioblastoma at ASCO 2017	05/06/17	CI
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	15/05/17	CI
ImmunoCellular Therapeutics and Memgen Announce Letter of Intent for Potential Joint Immuno-Oncology Collaboration	23/03/17	CI
ImmunoCellular Therapeutics, Ltd. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2016	09/03/17	CI
ImmunoCellular Seeks Acquisitions	09/03/17	CI
ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces Advances in Stem-to-T-Cell Research Program	06/03/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ImmunoCellular Therapeutics Ltd OTC Bulletin Board

Equities

IMUC

US4525361055

Highlights

Filters